Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

There's a new blood test to screen for colorectal cancer, but a new study found it's not as effective as a colonoscopy or ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

You need to repeat it yearly. Multitarget stool DNA test (Cologuard) This combines testing for blood with testing for DNA or gene changes in cells that can get into your poop from polyps ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

The FDA has approved the Cologuard Plus test for colorectal cancer screening in adults aged 45 years at average risk for colorectal cancer. The Food and Drug Administration (FDA) has approved the ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

But the new, just-launched version of its Cologuard test could spur top-line growth. The improved cancer diagnostic could also help Exact Sciences reach profitability. An updated version of Exact ...

Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...